

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number  
**WO 03/057155 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number: PCT/US02/41607
- (22) International Filing Date:  
27 December 2002 (27.12.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/342,398 27 December 2001 (27.12.2001) US
- (71) Applicants (for all designated States except US): **VAN ANDEL INSTITUTE** [US/US]; 333 Bostwick NE, Grand Rapids, MI 49503 (US). **THE UNITED STATES OF AMERICA**, as represented by the **DEPARTMENT OF VETERANS AFFAIRS** [US/US]; Department of Veterans Affairs, Office of General Counsel - PSG IV (024), 810 Vermont Avenue, NW, Washington, DC 20420 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HAY, Rick, V.**

[US/US]; 7954 Aspenwood Drive, S.E., Ada, MI 49301 (US). **CAO, Boliang** [CN/US]; 158 Donnybrook Court, N.E., Ada, MI 49301 (US). **RESAU, James, H.** [US/US]; 1413 Alexander, S.E., Grand Rapids, MI 49506 (US). **VANDE WOUDE, George, F.** [US/US]; 9451 Bailey Drive, N.E., Ada, MI 49301 (US). **GROSS, Milton, D.** [US/US]; 3695 Middleton, Ann Arbor, MI 48105 (US).


(74) Agent: **LIVNAT, Shmuel**; Venable, Baetjer, Howard & Civiletti, LLP, 1201 New York Avenue, NW, Suite 1000, P.O. Box 34385, Washington, DC 20043-9998 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: MONOCLONAL ANTIBODY IMAGING AND THERAPY OF TUMORS THAT EXPRESS MET AND BIND HEPATOCYTE GROWTH FACTOR



(57) Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met and its agonist ligand HGF. Disclosed herein are (a) mAbs and hybridoma cell lines that produce them, which mAbs antibodies are specific for Met and (b) combinations of anti-Met and anti-HGF mAbs. When detectably labeled, these antibodies are useful for imaging such tumors. Anti-Met mAb compositions and methods for scintigraphic detection, diagnosis, prognosis, monitoring and therapy of Met-bearing tumors are provided.

BEST AVAILABLE COPY

WO 03/057155 A2



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

**Declaration under Rule 4.17:**

— *of inventorship (Rule 4.17(iv)) for US only*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*




Fig. 1






Fig. 2




**Fig. 3B**



**Fig. 3A**

# Potential mechanisms of \*MAb binding to tumor cells

Indirect cell targeting  
with \*anti-HGF/SF



Direct cell targeting  
with \*anti-Met






Fig. 4



LNCaP




Fig. 5C/1

PC-3




Fig. 5C/2

DU145




Fig. 5C/3










Fig 6



**Fig. 7**












Met5 immunoprecipitates

Fig. 10




**Fig. 12A****Fig. 12B****Fig. 12C**

**Tumor**

**CNE-2**

**769-P**




1h

**Fig. 13A**


**CNE-2**

**769-P**




3d

**Fig. 13C**



1d

**Fig. 13B**



5d

**Fig. 13D**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**